Pharmacokinetics of metoprolol enantiomers following single and multiple administration of racemate in rat

被引:27
作者
Mostafavi, SA [1 ]
Foster, RT [1 ]
机构
[1] Univ Alberta, Fac Pharm & Pharmaceut Sci, Edmonton, AB T6G 2N8, Canada
关键词
metoprolol; pharmacokinetics; enantiomers; single dose; multiple dose;
D O I
10.1016/S0378-5173(00)00430-0
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The chiral beta-adrenergic blocking agent metoprolol (MET), which is marketed as a racemate, is a highly extracted drug with rapid absorption. The enantiomeric disposition of MET is reported following racemic administration as a single and as multiple ol al dosing foul times per day for four days in male Sprague-Dawley rats (n=6 in each group). Plasma was collected and enantiomeric concentrations of MET were determined using a stereospecific HPLC assay. The R/S ratio for AUC is not statistically different from unity either after single or after multiple administration of racemate. The oral clearance after single dose was 1.99 +/- 0.87 and 2.26 +/- 0.85 ml min(-1) kg(-1) for R- and S-MET, respectively. These values were decreased to 0.59 +/- 0.21 and 0.64 +/- 0.26 ml min(-1) kg(-1) after multiple administration of racemate. The corresponding values for the elimination half-lives were approximately 35 and 33 min after single and multiple dose administration For both enantiomers, respectively. These results may suggest a saturable first pass metabolism of MET as its enantiomers are accumulated in plasma following multiple dosing in the rat model. (C) 2000 Published by Elsevier science B.V. All rights reserved.
引用
收藏
页码:97 / 102
页数:6
相关论文
共 19 条
[1]  
APPELGREN G, 1974, ACTA PHARM SUEC, V11, P325
[2]   METOPROLOL - AN UPDATED REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC EFFICACY, IN HYPERTENSION, ISCHEMIC-HEART-DISEASE AND RELATED CARDIOVASCULAR DISORDERS [J].
BENFIELD, P ;
CLISSOLD, SP ;
BROGDEN, RN .
DRUGS, 1986, 31 (05) :376-429
[3]  
BHATTI MM, 1995, PHARM RES, V12, P23
[4]   PLASMA-LEVELS AND EFFECTS OF METOPROLOL AFTER SINGLE AND MULTIPLE ORAL DOSES [J].
COLLSTE, P ;
HAGLUND, K ;
VONBAHR, C .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1980, 27 (04) :441-449
[5]  
CRUICKSHANK JM, 1994, BETA BLOCKERS CLIN P, P631
[6]  
CRUICKSHANK JM, 1994, BETA BLOCKERS CLIN P, P354
[7]  
Hjalmarson Å, 1999, LANCET, V353, P2001
[8]   PHARMACOKINETIC AND PHARMACODYNAMIC PROPERTIES OF METOPROLOL IN PATIENTS WITH IMPAIRED RENAL-FUNCTION [J].
JORDO, L ;
ATTMAN, PO ;
AURELL, M ;
JOHANSSON, L ;
JOHNSSON, G ;
REGARDH, CG .
CLINICAL PHARMACOKINETICS, 1980, 5 (02) :169-180
[9]   SINGLE AND MULTIPLE DOSE PHARMACOKINETIC AND PHARMACODYNAMIC COMPARISON OF CONVENTIONAL AND SLOW-RELEASE METOPROLOL [J].
KENDALL, MJ ;
JOHN, VA ;
QUARTERMAN, CP ;
WELLING, PG .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1980, 17 (02) :87-92
[10]  
LANNARD MS, 1983, CLIN PHARMACOL THER, V34, P735